多潘立酮联合奥美拉唑对喉咽反流性疾病治疗的影响
|
摘要
目的探讨多潘立酮联合奥美拉唑对喉咽反流性疾病治疗的影响。方法选取我院2013年8月～2014年8月接收的86例喉咽反流性患者作为研究对象,采用抽签法分为观察组和对照组,各43例。对照组单纯使用多潘立酮进行治疗,观察组在对照组基础上加用奥美拉唑进行治疗,治疗时间均为4周,观察比较两组患者的临床疗效、唾液胃蛋白酶在1、2、3、4周转阴率、不良反应发生情况。结果观察组患者临床总有效率为93.02%,显著高于对照组,差异具有统计学意义(P <0.05);观察组患者唾液胃蛋白酶在1、2、3、4周转阴率分别为69.77%、83.72%、93.02%、95.35%,均显著高于对照组(P <0.05);观察组患者不良反应发生率显著低于对照组(P <0.05)。结论采用多潘立酮联合奥美拉唑治疗喉咽反流性疾病临床效果显著,有效改善唾液胃蛋白酶转阴情况,减少不良反应的发生,值得在临床上推广。
Objective To explore the effect of domperidone combined with omeprazole on the treatment of laryngopharyngeal reflux disease. Methods 86 patients of laryngopharyngeal reflux patients received in our hospital from August 2013 to August 2014 were selected and divided into observation group and control group in random law method, with 43 cases in each group. Patients in the control group were treated only with domperidone, while patients in the observation group were further treated with omeprazole. The clinical efficacy, turnover rate of saliva pepsin in 1, 2, 3 and 4 weeks, and the incidence of adverse reactions were observed and compared between the two groups.Results The total clinical efficiency of the observation group was 93.02%, significantly higher than that of the control group, and the difference was statistically significant(P < 0.05). The positive rate of salivary pepsin in 1, 2, 3, and4 weeks were 69.77%, 83.72%, 93.02% and 95.35%,respectively in the observation group, which were significantly higher than the control group(P < 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P < 0.05). Conclusion The use of domperidone combined with omeprazole in the treatment of laryngopharyngeal reflux disease has a significant clinical effect, which can effectively improve the negative conversion of saliva pepsin and reduce the occurrence of adverse reactions. Therefore, it is worth promoting in clinical practice.
Objective To explore the effect of domperidone combined with omeprazole on the treatment of laryngopharyngeal reflux disease. Methods 86 patients of laryngopharyngeal reflux patients received in our hospital from August 2013 to August 2014 were selected and divided into observation group and control group in random law method, with 43 cases in each group. Patients in the control group were treated only with domperidone, while patients in the observation group were further treated with omeprazole. The clinical efficacy, turnover rate of saliva pepsin in 1, 2, 3 and 4 weeks, and the incidence of adverse reactions were observed and compared between the two groups.Results The total clinical efficiency of the observation group was 93.02%, significantly higher than that of the control group, and the difference was statistically significant(P < 0.05). The positive rate of salivary pepsin in 1, 2, 3, and4 weeks were 69.77%, 83.72%, 93.02% and 95.35%,respectively in the observation group, which were significantly higher than the control group(P < 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P < 0.05). Conclusion The use of domperidone combined with omeprazole in the treatment of laryngopharyngeal reflux disease has a significant clinical effect, which can effectively improve the negative conversion of saliva pepsin and reduce the occurrence of adverse reactions. Therefore, it is worth promoting in clinical practice.
引文
[1]邹超鹏.奥美拉唑肠溶片与多潘立酮片联合治疗喉咽反流性疾病的疗效观察[J].中国医院用药评价与分析,2016,16(4):444-446.
[2]张萍,饶远生,张丽川,等.奥美拉唑联合多潘立酮治疗阻塞性睡眠呼吸暂停低通气综合征伴咽喉反流性疾病的临床效果[J].中国医药, 2016, 11(5):667-671.
[3]付国新,郭月婷,张冬梅.探讨奥美拉唑联合多潘立酮治疗咽喉反流的临床疗效[J].中国卫生标准管理,2017,8(1):75-76.
[4]陈贤忠.磷酸铝凝胶联合多潘立酮治疗喉咽反流性疾病的临床疗效观察[J].吉林医学,2016,37(3):584-585.
[5]刘石.喉咽返流疾病的临床诊断及应对措施论述[J].中外医疗,2014,33(2):17.
[6]吴贤敏,上官翰京,陈晓云,等.中西医结合治疗由喉咽反流导致的咽喉炎疗效分析[J].温州医科大学学报,2014, 44(1):51-54.
[7]刘兆云,陈轩,郭炜伦,等.多潘立酮联合埃索美拉唑治疗胃食管反流病的临床疗效[J].检验医学与临床,2016, 13(4):516-517.
[8]韩军,杜雅平.奥美拉唑治疗92例反流性咽喉炎的临床效果观察[J].航空航天医学杂志, 2016, 27(3):239-240.
[9]黄勇,刘丽珍,金忠芹,等.奥美拉唑联合多潘立酮治疗小儿胃食管反流病的疗效观察[J].现代生物医学进展, 2017, 17(10):1859-1862.
[10]马红录,张贞鲁.蒲元和胃胶囊联合奥美拉唑和多潘立酮治疗反流性食管炎的疗效观察[J].现代药物与临床, 2016, 31(11):1746-1749.
[11]周祥荣.埃索美拉唑联合多潘立酮治疗反流性食管炎的临床疗效[J].四川医学, 2016, 37(3):327-329.
[12]秦高博,夏荣松.奥美拉唑联合胃动力药治疗反流性食管炎的Meta分析[J].医学综述, 2014, 20(11):2052-2055.
[13]陈姗,李兰.并发咽喉反流的睡眠呼吸暂停低通气综合征儿童临床治疗初步观察[J].中华耳鼻咽喉头颈外科杂志, 2014, 49(5):379-383.
[14]唐硕.奥美拉唑联合多潘立酮治疗小儿反流性食管炎的临床疗效观察[J].临床医学工程, 2016, 23(11):1527-1528.
[15]张国华,容庆丰.喉咽反流与幽门螺杆菌感染的相关性分析[J].现代医院,2018,18(8):1201-1203.
[16]魏春晖.中西医结合治疗咽喉反流合并咽喉炎的临床疗效[J].中国耳鼻咽喉颅底外科杂志, 2017, 23(3):226-229.
[2]张萍,饶远生,张丽川,等.奥美拉唑联合多潘立酮治疗阻塞性睡眠呼吸暂停低通气综合征伴咽喉反流性疾病的临床效果[J].中国医药, 2016, 11(5):667-671.
[3]付国新,郭月婷,张冬梅.探讨奥美拉唑联合多潘立酮治疗咽喉反流的临床疗效[J].中国卫生标准管理,2017,8(1):75-76.
[4]陈贤忠.磷酸铝凝胶联合多潘立酮治疗喉咽反流性疾病的临床疗效观察[J].吉林医学,2016,37(3):584-585.
[5]刘石.喉咽返流疾病的临床诊断及应对措施论述[J].中外医疗,2014,33(2):17.
[6]吴贤敏,上官翰京,陈晓云,等.中西医结合治疗由喉咽反流导致的咽喉炎疗效分析[J].温州医科大学学报,2014, 44(1):51-54.
[7]刘兆云,陈轩,郭炜伦,等.多潘立酮联合埃索美拉唑治疗胃食管反流病的临床疗效[J].检验医学与临床,2016, 13(4):516-517.
[8]韩军,杜雅平.奥美拉唑治疗92例反流性咽喉炎的临床效果观察[J].航空航天医学杂志, 2016, 27(3):239-240.
[9]黄勇,刘丽珍,金忠芹,等.奥美拉唑联合多潘立酮治疗小儿胃食管反流病的疗效观察[J].现代生物医学进展, 2017, 17(10):1859-1862.
[10]马红录,张贞鲁.蒲元和胃胶囊联合奥美拉唑和多潘立酮治疗反流性食管炎的疗效观察[J].现代药物与临床, 2016, 31(11):1746-1749.
[11]周祥荣.埃索美拉唑联合多潘立酮治疗反流性食管炎的临床疗效[J].四川医学, 2016, 37(3):327-329.
[12]秦高博,夏荣松.奥美拉唑联合胃动力药治疗反流性食管炎的Meta分析[J].医学综述, 2014, 20(11):2052-2055.
[13]陈姗,李兰.并发咽喉反流的睡眠呼吸暂停低通气综合征儿童临床治疗初步观察[J].中华耳鼻咽喉头颈外科杂志, 2014, 49(5):379-383.
[14]唐硕.奥美拉唑联合多潘立酮治疗小儿反流性食管炎的临床疗效观察[J].临床医学工程, 2016, 23(11):1527-1528.
[15]张国华,容庆丰.喉咽反流与幽门螺杆菌感染的相关性分析[J].现代医院,2018,18(8):1201-1203.
[16]魏春晖.中西医结合治疗咽喉反流合并咽喉炎的临床疗效[J].中国耳鼻咽喉颅底外科杂志, 2017, 23(3):226-229.